PCVX - Vaxcyte, Inc.
About Vaxcyte, Inc. (https://vaxcyte.com)
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Grant E. Pickering | Co-Founder, Chief Executive Officer & Director | 1968 | $1,444,730 USD |
| Andrew L. Guggenhime | President & Chief Financial Officer | 1968 | $960,230 USD |
| Mikhail Eydelman | Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary | 1982 | $752,712 USD |
| Harp Dhaliwal | Chief Technical Operations Officer | 1973 | $743,618 USD |
| James Wassil | Executive Vice President & Chief Operating Officer | 1969 | $614,730 USD |
| Chris Griffith | Chief Business & Strategy Officer | – | – |
| Elvia Cowan | Senior VP of Finance & Chief Accounting Officer | 1973 | – |
| Janet Graesser | Senior Vice President of Corporate Affairs | – | – |
| Jeff Fairman | Co-Founder & Vice President of Research | 1964 | – |
| Jeff Macdonald | Executive Director of Investor Relations | – | – |
| Mike Mullette | Chief Commercial Officer | – | – |
| Sam Iki | Senior Vice President of Project Management | – | – |
| Whitney Jones | Chief People Officer | – | – |